IPL576,092, a novel anti-inflammatory compound, inhibits leukocyte infiltration and changes in lung function in response to allergen challenge

C. E. Kasserra, P. Harris, G. R. Stenton, W. Abraham, J. M. Langlands

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

IPL576,092, a lead compound from a novel class of polyhydroxylated sterols, was tested in models of allergen-induced bronchoconstriction and airway inflammation. In a rat ovalbumin lung inflammation model, orally administered IPL576,092 significantly inhibited the challenge-mediated increase in total bronchoalveolar lavage leukocyte numbers, and macrophage and lymphocyte infiltration (1-10 mg/kg/day). There was a similar trend towards inhibition of eosinophil and neutrophil accumulation. Sheep were treated with IPL576,092 by inhalation (400 μg/kg/day), and lung resistance and airway hyper-responsiveness (AHR) were determined after Ascaris suum challenge. IPL576,092 significantly reduced the early and late phase bronchoconstrictor responses by 63±4.6 and 84±4.6%, respectively. IPL576,092 also blocked AHR (2.2±5.7% change from pre-challenge PC400), whereas control animals showed a 62.2±2.6% decrease in the PC400 (p<0.05). Oral IPL576,092 (5 mg/kg/day) also significantly decreased hyper-reactivity in mice. In a guinea pig model, IPL576,092 (5 mg/kg/day) significantly protected against allergen-induced increases in lung resistance (11.4±2.3 control versus 4.8±01.5 IPL576,092, area under the curve) and inhibited the increase in lung elastance (280±58 control versus 167±52 IPL576,092, p<0.05). IPL576,092, unlike dexamethasone, did not significantly decrease rat serum corticosterone levels or thymus and spleen weights, supporting a mechanism of action different from classic glucocorticoids. IPL576,092 significantly attenuates characteristics of an asthmatic response, indicating therapeutic potential for this drug class.

Original languageEnglish
Pages (from-to)309-318
Number of pages10
JournalPulmonary Pharmacology and Therapeutics
Volume17
Issue number5
DOIs
StatePublished - Oct 1 2004
Externally publishedYes

Fingerprint

Infiltration
Allergens
Leukocytes
Anti-Inflammatory Agents
Lung
Respiratory Hypersensitivity
Rats
IPL576,092
Bronchoconstrictor Agents
Ascaris suum
Lead compounds
Thymus
Bronchoconstriction
Lymphocytes
Macrophages
Ovalbumin
Bronchoalveolar Lavage
Sterols
Corticosterone
Leukocyte Count

Keywords

  • Airway hyperresponsiveness
  • Asthma
  • Bronchoconstriction
  • Inflammation
  • Therapeutic

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology

Cite this

IPL576,092, a novel anti-inflammatory compound, inhibits leukocyte infiltration and changes in lung function in response to allergen challenge. / Kasserra, C. E.; Harris, P.; Stenton, G. R.; Abraham, W.; Langlands, J. M.

In: Pulmonary Pharmacology and Therapeutics, Vol. 17, No. 5, 01.10.2004, p. 309-318.

Research output: Contribution to journalArticle

Kasserra, C. E. ; Harris, P. ; Stenton, G. R. ; Abraham, W. ; Langlands, J. M. / IPL576,092, a novel anti-inflammatory compound, inhibits leukocyte infiltration and changes in lung function in response to allergen challenge. In: Pulmonary Pharmacology and Therapeutics. 2004 ; Vol. 17, No. 5. pp. 309-318.
@article{e8bf46fc8b3a4410b0e578cb080a5e67,
title = "IPL576,092, a novel anti-inflammatory compound, inhibits leukocyte infiltration and changes in lung function in response to allergen challenge",
abstract = "IPL576,092, a lead compound from a novel class of polyhydroxylated sterols, was tested in models of allergen-induced bronchoconstriction and airway inflammation. In a rat ovalbumin lung inflammation model, orally administered IPL576,092 significantly inhibited the challenge-mediated increase in total bronchoalveolar lavage leukocyte numbers, and macrophage and lymphocyte infiltration (1-10 mg/kg/day). There was a similar trend towards inhibition of eosinophil and neutrophil accumulation. Sheep were treated with IPL576,092 by inhalation (400 μg/kg/day), and lung resistance and airway hyper-responsiveness (AHR) were determined after Ascaris suum challenge. IPL576,092 significantly reduced the early and late phase bronchoconstrictor responses by 63±4.6 and 84±4.6{\%}, respectively. IPL576,092 also blocked AHR (2.2±5.7{\%} change from pre-challenge PC400), whereas control animals showed a 62.2±2.6{\%} decrease in the PC400 (p<0.05). Oral IPL576,092 (5 mg/kg/day) also significantly decreased hyper-reactivity in mice. In a guinea pig model, IPL576,092 (5 mg/kg/day) significantly protected against allergen-induced increases in lung resistance (11.4±2.3 control versus 4.8±01.5 IPL576,092, area under the curve) and inhibited the increase in lung elastance (280±58 control versus 167±52 IPL576,092, p<0.05). IPL576,092, unlike dexamethasone, did not significantly decrease rat serum corticosterone levels or thymus and spleen weights, supporting a mechanism of action different from classic glucocorticoids. IPL576,092 significantly attenuates characteristics of an asthmatic response, indicating therapeutic potential for this drug class.",
keywords = "Airway hyperresponsiveness, Asthma, Bronchoconstriction, Inflammation, Therapeutic",
author = "Kasserra, {C. E.} and P. Harris and Stenton, {G. R.} and W. Abraham and Langlands, {J. M.}",
year = "2004",
month = "10",
day = "1",
doi = "10.1016/j.pupt.2004.07.003",
language = "English",
volume = "17",
pages = "309--318",
journal = "Pulmonary Pharmacology and Therapeutics",
issn = "1094-5539",
publisher = "Academic Press Inc.",
number = "5",

}

TY - JOUR

T1 - IPL576,092, a novel anti-inflammatory compound, inhibits leukocyte infiltration and changes in lung function in response to allergen challenge

AU - Kasserra, C. E.

AU - Harris, P.

AU - Stenton, G. R.

AU - Abraham, W.

AU - Langlands, J. M.

PY - 2004/10/1

Y1 - 2004/10/1

N2 - IPL576,092, a lead compound from a novel class of polyhydroxylated sterols, was tested in models of allergen-induced bronchoconstriction and airway inflammation. In a rat ovalbumin lung inflammation model, orally administered IPL576,092 significantly inhibited the challenge-mediated increase in total bronchoalveolar lavage leukocyte numbers, and macrophage and lymphocyte infiltration (1-10 mg/kg/day). There was a similar trend towards inhibition of eosinophil and neutrophil accumulation. Sheep were treated with IPL576,092 by inhalation (400 μg/kg/day), and lung resistance and airway hyper-responsiveness (AHR) were determined after Ascaris suum challenge. IPL576,092 significantly reduced the early and late phase bronchoconstrictor responses by 63±4.6 and 84±4.6%, respectively. IPL576,092 also blocked AHR (2.2±5.7% change from pre-challenge PC400), whereas control animals showed a 62.2±2.6% decrease in the PC400 (p<0.05). Oral IPL576,092 (5 mg/kg/day) also significantly decreased hyper-reactivity in mice. In a guinea pig model, IPL576,092 (5 mg/kg/day) significantly protected against allergen-induced increases in lung resistance (11.4±2.3 control versus 4.8±01.5 IPL576,092, area under the curve) and inhibited the increase in lung elastance (280±58 control versus 167±52 IPL576,092, p<0.05). IPL576,092, unlike dexamethasone, did not significantly decrease rat serum corticosterone levels or thymus and spleen weights, supporting a mechanism of action different from classic glucocorticoids. IPL576,092 significantly attenuates characteristics of an asthmatic response, indicating therapeutic potential for this drug class.

AB - IPL576,092, a lead compound from a novel class of polyhydroxylated sterols, was tested in models of allergen-induced bronchoconstriction and airway inflammation. In a rat ovalbumin lung inflammation model, orally administered IPL576,092 significantly inhibited the challenge-mediated increase in total bronchoalveolar lavage leukocyte numbers, and macrophage and lymphocyte infiltration (1-10 mg/kg/day). There was a similar trend towards inhibition of eosinophil and neutrophil accumulation. Sheep were treated with IPL576,092 by inhalation (400 μg/kg/day), and lung resistance and airway hyper-responsiveness (AHR) were determined after Ascaris suum challenge. IPL576,092 significantly reduced the early and late phase bronchoconstrictor responses by 63±4.6 and 84±4.6%, respectively. IPL576,092 also blocked AHR (2.2±5.7% change from pre-challenge PC400), whereas control animals showed a 62.2±2.6% decrease in the PC400 (p<0.05). Oral IPL576,092 (5 mg/kg/day) also significantly decreased hyper-reactivity in mice. In a guinea pig model, IPL576,092 (5 mg/kg/day) significantly protected against allergen-induced increases in lung resistance (11.4±2.3 control versus 4.8±01.5 IPL576,092, area under the curve) and inhibited the increase in lung elastance (280±58 control versus 167±52 IPL576,092, p<0.05). IPL576,092, unlike dexamethasone, did not significantly decrease rat serum corticosterone levels or thymus and spleen weights, supporting a mechanism of action different from classic glucocorticoids. IPL576,092 significantly attenuates characteristics of an asthmatic response, indicating therapeutic potential for this drug class.

KW - Airway hyperresponsiveness

KW - Asthma

KW - Bronchoconstriction

KW - Inflammation

KW - Therapeutic

UR - http://www.scopus.com/inward/record.url?scp=5144223575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5144223575&partnerID=8YFLogxK

U2 - 10.1016/j.pupt.2004.07.003

DO - 10.1016/j.pupt.2004.07.003

M3 - Article

VL - 17

SP - 309

EP - 318

JO - Pulmonary Pharmacology and Therapeutics

JF - Pulmonary Pharmacology and Therapeutics

SN - 1094-5539

IS - 5

ER -